Increased Risk of Thrombotic Events in Cold Agglutinin Disease: A 10-year Retrospective Analysis

Overview

Journal Res Pract Thromb Haemost

Publisher Elsevier

Date 2020 Jun 18

PMID 32548562

Citations 28

Authors

Catherine M Broome

Julia M Cunningham

Megan Mullins

Xiaohui Jiang

Lauren C Bylsma

Jon P Fryzek

Adam Rosenthal

Affiliations

Soon will be listed here.

Abstract

Background: Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia mediated by IgM autoantibodies that trigger hemolysis via classical complement pathway. Increased incidence of thrombotic events (TEs) has been reported in patients with other forms of hemolysis. The incidence of TEs in patients with CAD is unknown.

Objective: Evaluate TE risk in patients with CAD.

Patients/methods: This is a matched cohort comparison study evaluating the risk of TEs in patients with CAD and without CAD over a 10-year period. A total of 608 patients with CAD were identified in the Optum Claims-Clinical data set by reviewing clinical notes for CAD terms and matched with up to 10 patients without CAD (N = 5873). TEs were defined as the first medical claim for a TE using International Classification of Diseases, Ninth and Tenth Revision codes. Cox regression models were used to estimate time to first TE. Sensitivity analyses were conducted to estimate TE risk among patients with primary CAD.

Results: At least 1 TE occurred in 29.6% of patients with CAD and 17.6% of patients without CAD. The proportion of patients experiencing venous, arterial, and cerebral TEs were each higher among CAD patients. The overall risk of having TEs was higher in patients with CAD (adjusted hazard ratio [aHR], 1.94; 95% confidence interval [CI], 1.64-2.30). Patients with presumed primary CAD also demonstrated an increased risk of TEs (aHR, 1.80; 95% CI, 1.46-2.22). Patients with CAD with the fewest comorbidities had 2.44-fold higher risk of having a TE (95% CI, 1.70-3.52).

Conclusions: Patients with CAD have an increased risk of TEs when compared with a matched non-CAD population.

Citing Articles

Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy.

Barcellini W, Fattizzo B Transfus Med Hemother. 2024; 51(5):321-331.

PMID: 39371250 PMC: 11452171. DOI: 10.1159/000540475.

Sutimlimab for Cold Agglutinin Disease.

Reid M, Fedutes Henderson B J Adv Pract Oncol. 2024; 15(6):389-395.

PMID: 39328891 PMC: 11424156. DOI: 10.6004/jadpro.2024.15.6.4.

Management of autoimmune haemolytic anaemia in low-to-middle income countries: current challenges and the way forward.

Datta S, Berentsen S Lancet Reg Health Southeast Asia. 2024; 23:100343.

PMID: 38601175 PMC: 11004394. DOI: 10.1016/j.lansea.2023.100343.

Clinical and laboratory characteristics of patients with cold agglutinin disease: A retrospective analysis at a tertiary medical center.

Mehrotra H, Otrock Z Asian J Transfus Sci. 2024; 17(2):229-233.

PMID: 38274972 PMC: 10807533. DOI: 10.4103/ajts.ajts_65_23.

Monoclonal Gammopathy of Undetermined Cardiovascular Significance; Current Evidence and Novel Insights.

Tentolouris A, Ntanasis-Stathopoulos I, Gavriatopoulou M, Andreadou I, Terpos E J Cardiovasc Dev Dis. 2023; 10(12).

PMID: 38132652 PMC: 10743961. DOI: 10.3390/jcdd10120484.

References

Hillmen P, Muus P, Duhrsen U, Risitano A, Schubert J, Luzzatto L . Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007; 110(12):4123-8. DOI: 10.1182/blood-2007-06-095646. View

Chapin J, Terry H, Kleinert D, Laurence J . The role of complement activation in thrombosis and hemolytic anemias. Transfus Apher Sci. 2016; 54(2):191-8. DOI: 10.1016/j.transci.2016.04.008. View

Rother R, Bell L, Hillmen P, Gladwin M . The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005; 293(13):1653-62. DOI: 10.1001/jama.293.13.1653. View

Austin P . Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes. J Clin Epidemiol. 2009; 63(1):46-55. DOI: 10.1016/j.jclinepi.2009.03.012. View

Roth A, Bommer M, Huttmann A, Herich-Terhurne D, Kuklik N, Rekowski J . Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2018; 2(19):2543-2549. PMC: 6177646. DOI: 10.1182/bloodadvances.2018024190. View

Michel M . Classification and therapeutic approaches in autoimmune hemolytic anemia: an update. Expert Rev Hematol. 2011; 4(6):607-18. DOI: 10.1586/ehm.11.60. View

Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J . Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43(11):1130-9. DOI: 10.1097/01.mlr.0000182534.19832.83. View

Hillmen P, Lewis S, Bessler M, Luzzatto L, Dacie J . Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995; 333(19):1253-8. DOI: 10.1056/NEJM199511093331904. View

Grosse S, Nelson R, Nyarko K, Richardson L, Raskob G . The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res. 2015; 137:3-10. PMC: 4706477. DOI: 10.1016/j.thromres.2015.11.033. View

10.

Sanfilippo K, Wang T, Gage B, Liu W, Carson K . Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data. Thromb Res. 2015; 135(4):616-20. PMC: 4361236. DOI: 10.1016/j.thromres.2015.01.012. View

11.

LAcqua C, Hod E . New perspectives on the thrombotic complications of haemolysis. Br J Haematol. 2014; 168(2):175-85. DOI: 10.1111/bjh.13183. View

12.

Fang M, Fan D, Sung S, Witt D, Schmelzer J, Steinhubl S . Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism: The CVRN VTE Study. Med Care. 2017; 55(12):e137-e143. PMC: 5125903. DOI: 10.1097/MLR.0000000000000524. View

13.

Zhong H, Yazdanbakhsh K . Hemolysis and immune regulation. Curr Opin Hematol. 2018; 25(3):177-182. PMC: 6309361. DOI: 10.1097/MOH.0000000000000423. View

14.

Broome C, Cunningham J, Mullins M, Jiang X, Bylsma L, Fryzek J . Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis. Res Pract Thromb Haemost. 2020; 4(4):628-635. PMC: 7292660. DOI: 10.1002/rth2.12333. View

15.

Beckman M, Hooper W, Critchley S, Ortel T . Venous thromboembolism: a public health concern. Am J Prev Med. 2010; 38(4 Suppl):S495-501. DOI: 10.1016/j.amepre.2009.12.017. View

16.

Li J, Panucci G, Moeny D, Liu W, Maro J, Toh S . Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous-Cycle Combined Oral Contraceptives: A Safety Study Using the Sentinel Distributed Database. JAMA Intern Med. 2018; 178(11):1482-1488. PMC: 6248208. DOI: 10.1001/jamainternmed.2018.4251. View

17.

Schrezenmeier H, Muus P, Socie G, Szer J, Urbano-Ispizua A, Maciejewski J . Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014; 99(5):922-9. PMC: 4008114. DOI: 10.3324/haematol.2013.093161. View

18.

Weitz I . Complement the hemostatic system: an intimate relationship. Thromb Res. 2014; 133 Suppl 2:S117-21. DOI: 10.1016/S0049-3848(14)50020-5. View

19.

Brodsky R . Complement in hemolytic anemia. Blood. 2015; 126(22):2459-65. PMC: 11270838. DOI: 10.1182/blood-2015-06-640995. View

20.

Mullins M, Jiang X, Bylsma L, Fryzek J, Reichert H, Chen E . Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization. Blood Adv. 2018; 1(13):839-848. PMC: 5727809. DOI: 10.1182/bloodadvances.2017004390. View